Pulmonary eosinophilia
Therapeutic area
Hematology
Rare disease
No
- Definition
- A condition characterized by infiltration of the lung with eosinophils due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Pulmonary eosinophilia
- Alternative names
- pulmonary eosinophilia
- Therapeutic area
- Hematology
- Disease mechanisms
- Syndromic
- Severity
- Moderate
- Cardiology
- Hematology
- Immunology
- Neuromuscular Disease
- Rheumatology
- MONDO ID
- MONDO:0004802
- Parent condition
- MONDO:0015691
Related records
Broader conditions (17)
- Cardiomyopathy
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Eosinophil disorder
- Heart disorder
- Hematologic disorder
- Human disease
- Hypereosinophilic syndrome
- Immune system disorder
- Intrinsic cardiomyopathy
- Leukocyte disorder
- Muscle tissue disorder
- Musculoskeletal system disorder
- Non-familial restrictive cardiomyopathy
- Restrictive cardiomyopathy
- Syndromic disease
Narrower conditions (1)
- Idiopathic acute eosinophilic pneumonia
Trials (102)
- A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
- A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
- A Non-interventional, Prospective Study With Benralizumab
- A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
- A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
- A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
- A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
- A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
- A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
- A Study of Depemokimab in Participants of 6 to 11 Years of Age
- A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
- A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
- A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
- A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
- A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
- A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma